RxDoctor Payments DataLook up a doctor →

Scott Hadfield, PA

Surgical · Salt Lake City, UTNPI 1770836397

Payments from drug & device makers

$9,851in general payments, 2019–2025

Across 470 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$839
  • Dendreon Pharmaceuticals LLC$761
  • Endo Pharmaceuticals Inc.$642
  • AbbVie$502
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$1,47215%
  • Food & beverage$7,84580%
  • Education$5155%
  • Other$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,851 in reported general payments places this provider in the 95th percentile of 121 surgical providers in Utah.

See all surgical providers in Utah

Medicare billing

Part B allowed, 2024
$117,304
Medicare patients
490
Services billed
7,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron137$131,756
MyrbetriqMirabegron119$111,187
Tamsulosin Hcl612$9,175
Testosterone Cypionate189$8,602
Testosterone30$8,108
Methenamine Hippurate61$7,195
Solifenacin Succinate91$4,551
Potassium Citrate ErPotassium Citrate36$4,004
Fesoterodine Fumarate ErFesoterodine Fumarate11$2,551
NitrofurantoinNitrofurantoin Macrocrystal21$1,252
Alfuzosin Hcl ErAlfuzosin Hcl49$1,131
Finasteride67$984
Oxybutynin Chloride ErOxybutynin Chloride32$810
Ciprofloxacin Hcl76$742
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav67$681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$839$131,756137 claims
Astellas Pharma US IncMyrbetriq$1,269$111,187119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 121 surgical providers in Utah.

Other surgical in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →